Who Owns Organigram Holdings Company?

Organigram Holdings Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Organigram Holdings Inc.?

The ownership structure of a company is a critical factor influencing its strategic direction and operational priorities. For Organigram Holdings Inc., understanding its ownership is key to grasping its market position and future potential within the dynamic cannabis sector. The company's journey, marked by its initial public offering, significantly reshaped who holds influence and investment in the organization.

Organigram Holdings Inc., established in 2013 in Moncton, New Brunswick, Canada, has emerged as a prominent player in the cannabis industry. It is recognized for its diverse product range, including dried flower, pre-rolls, edibles, vapes, and concentrates, with its Organigram Holdings BCG Matrix reflecting its market presence. The company operates advanced facilities across Canada, contributing to its status as Canada's number one cannabis company by market share as of May 2025.

Delving into the specifics of Organigram Holdings ownership reveals a complex interplay of founding interests, institutional backing, and public market participation. Initially, the founders and early investors held significant stakes. As the company grew and pursued its initial public offering, the ownership base broadened considerably, bringing in institutional investors and a wider array of individual shareholders. This transition is vital for anyone looking to understand Organigram stock ownership and the broader Organigram investors landscape. Identifying Organigram Holdings major shareholders often requires reviewing public filings and investor relations information, which detail the distribution of shares and the influence of key entities.

The question of 'Who owns Organigram' is multifaceted, encompassing not just large institutional holders but also the collective ownership by the public through its stock market listing. Understanding the percentage of Organigram Holdings owned by its executives and the board of directors is also a key aspect of corporate governance. The company's acquisition history ownership and its investor relations contact are important for those seeking detailed shareholder information. Organigram Holdings Inc. financial reports ownership details are typically available through its annual general meeting shareholder questions and other corporate communications, providing transparency on its shareholder base.

As a publicly traded entity, Organigram Holdings Inc. stock symbol and ownership are readily accessible through financial market data providers. The dynamics of insider trading ownership and the company's dividend policy ownership can offer further insights into the confidence and investment strategies of those closely connected to the company. The Organigram Holdings Inc. company structure ownership, including the roles of its board of directors, is fundamental to its overall corporate governance ownership framework.

Organigram Holdings Inc. was established in 2013 in Moncton, New Brunswick, Canada. Its foundational goal was to become a leading producer and distributor of both medical and recreational cannabis products. While comprehensive details concerning the exact equity distribution among its initial founders are not readily available in current public records, the company quickly distinguished itself through its early emphasis on producing organic and sustainably grown cannabis. The initial ownership structure would have predominantly featured the founders holding the majority of the equity, likely supplemented by capital from early angel investors or personal funds from friends and family.

The company commenced its medical cannabis production in 2014 and secured its license for recreational cannabis production and distribution in 2016. These were pivotal moments that significantly influenced its early valuation and its capacity to attract further investment. Standard practices for early-stage companies often include vesting schedules or clauses for future share dilution to motivate founders and key personnel, though the specific terms of Organigram's initial arrangements remain undisclosed publicly. The founding team's dedication to product quality and market expansion, demonstrated by its swift licensing progress and product development, set the stage for its eventual public listing and attracted a broader base of investors.

Founding Vision

Organigram was founded with a clear vision to be a premier producer of cannabis products. This early focus on quality and sustainability shaped its initial market perception.

Early Operations

Production of medical cannabis began in 2014, followed by obtaining a license for recreational cannabis in 2016. These milestones were crucial for its growth trajectory.

Initial Ownership Structure

Founders likely held the primary equity stake, supported by early angel investors and personal capital. Specific equity splits from inception are not publicly detailed.

Licensing Milestones

Securing licenses for both medical and recreational cannabis production were key achievements. These licenses were vital for market entry and expansion.

Early Investment Factors

The company's commitment to quality and its rapid licensing progress were instrumental in attracting early investment. These factors laid the groundwork for future funding rounds.

Founder Incentives

Common early-stage company practices like vesting schedules and dilution clauses are likely to have been in place. However, specific details for Organigram are not publicly disclosed.

Organigram Holdings Inc. Early Development

The early years of Organigram Holdings Inc. were characterized by a strong focus on establishing its operational capabilities and securing necessary licenses. This period was crucial for building a foundation for its future growth and market presence. The company's strategic decisions during this phase directly influenced its ability to attract investment and scale its operations, as detailed in its Growth Strategy of Organigram Holdings.

• Founded in 2013 in Moncton, New Brunswick.
• Initial vision focused on organic and sustainable cannabis production.
• Began medical cannabis production in 2014.
• Received license for recreational cannabis in 2016.
• Early ownership likely comprised founders and initial investors.

Organigram Holdings SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Organigram Holdings Inc. transitioned to public trading on the Toronto Stock Exchange (TSX) on August 22, 2019, under the ticker OGI, following its previous listing on the TSX Venture Exchange. The company's common shares are also accessible on the Nasdaq Global Select Market, maintaining the same OGI symbol. As of July 18, 2025, Organigram's market capitalization is approximately $196 million.

A pivotal development in Organigram's ownership landscape was the strategic investment by British American Tobacco plc (BAT), executed through its subsidiary BT DE Investments Inc. This relationship began with an initial equity investment in March 2021, culminating in a follow-on investment of C$124.6 million, finalized in three stages with the last tranche closing on February 28, 2025. This partnership established a venture named Jupiter, aimed at global expansion within emerging cannabis markets. As of March 2025, approximately C$57.8 million remained available within this pool for further strategic allocations, following initial investments in Sanity Group and Open Book Extracts. BAT is recognized as the largest shareholder in Organigram Holdings.

As of March 31, 2025, institutional investors held approximately 4.82% of Organigram Global Inc.'s total outstanding shares, with the total value of these holdings nearing $9 million. Prominent institutional shareholders at that time included Tidal Investments LLC, holding 2,522,523 shares, Renaissance Technologies LLC with 1,004,748 shares, and Advisorshares Investments LLC, which owned 845,954 shares. By July 2025, other significant institutional investors identified were Baader Bank INC, DFA INVESTMENT TRUST CO - The Canadian Small Company Series, and Mariner, LLC. This ownership structure highlights a substantial presence of individual investors, who collectively own about 85.96% of the stock, alongside a notable 10.49% held by insiders and the strategic stake held by institutional and corporate entities.

Organigram Holdings Ownership Breakdown

Understanding Organigram Holdings Inc. shareholders is key to grasping its corporate structure. The company's ownership is a mix of retail, insider, and institutional investors.

• British American Tobacco plc (BAT) is the largest shareholder.
• Institutional ownership was around 4.82% as of March 31, 2025.
• Retail investors constitute the majority of ownership.
• Insiders hold a significant portion of the company's shares.
• The company's stock is publicly traded on both the TSX and Nasdaq.

Organigram Holdings PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Organigram Global Inc.'s board of directors is comprised of ten individuals elected by shareholders as of March 24, 2025. This group includes Peter Amirault, Dexter John, Stephen Smith, Geoffrey Machum, Sherry Porter, Marni Wieshofer, Simon Ashton, Karina Gehring, Craig Harris, and Beena Goldenberg. Beena Goldenberg, who also serves as the company's CEO, is scheduled to retire at the close of the fiscal year on September 30, 2025. The composition of the board reflects a blend of independent directors and those nominated by significant investors, underscoring the influence of major shareholders on the company's strategic direction.

Simon Ashton's appointment to the board in February 2022, as a nominee of BT DE Investments Inc. (BAT), highlights the governance rights afforded to strategic investors. This arrangement, detailed in an amended and restated investor rights agreement from January 23, 2024, allows BAT to appoint up to 20% of the board, provided they maintain specific ownership thresholds. This provision grants BAT considerable influence over board representation, a direct consequence of its substantial investment and strategic partnership. Currently, there have been no public reports of proxy battles or activist campaigns significantly impacting the company's decision-making, suggesting a stable governance framework, though one clearly shaped by its key strategic partner.

The voting power for Organigram's common shares operates on a one-share-one-vote basis, without provisions for cumulative or similar voting rights. This standard structure means that voting power is directly proportional to the number of shares held. However, the strategic investment by BT DE Investments Inc. (BAT) introduces a layer of influence through its governance rights, allowing it to nominate a portion of the board members. This mechanism ensures that significant investors have a voice in the company's leadership and strategic decisions, a common practice in companies with substantial strategic partnerships. Understanding these dynamics is key to grasping Organigram Holdings ownership and how decisions are made, impacting Organigram stock ownership.

Understanding Board Influence

The board of directors at Organigram Holdings Inc. is a critical component of its corporate governance. The influence of major shareholders, like BT DE Investments Inc. (BAT), is formalized through specific investor rights agreements.

• BAT has the right to appoint up to 20% of the board.
• This right is contingent on maintaining certain share ownership levels.
• The CEO, Beena Goldenberg, also holds a board seat.
• Her retirement at the end of fiscal year 2025 will necessitate a board transition.
• The structure reflects a balance between shareholder representation and independent oversight.

Organigram Holdings Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Organigram Holdings Inc. has experienced significant shifts in its ownership landscape, driven by strategic investments and key acquisitions. These developments have reshaped its shareholder base and positioned the company for future growth. Understanding these trends is crucial for anyone looking into Organigram Holdings ownership.

A pivotal moment in Organigram's recent history was the substantial equity investment from BT DE Investments Inc., a subsidiary of BAT. The final tranche of this C$124.6 million investment closed on February 28, 2025. This infusion of capital not only strengthened BAT's stake but also provided Organigram with approximately C$57.8 million for its Jupiter strategic investment pool, aimed at exploring new global cannabis opportunities. This strategic partnership highlights a trend towards consolidation and significant backing from larger entities within the industry, impacting Organigram stock ownership.

The company's strategic moves, including acquisitions and capital raises, reflect a broader industry trend of consolidation and expansion. Organigram's focus on international markets, such as Germany and the UK, alongside its entry into the U.S. hemp-derived market, demonstrates a forward-looking approach to diversification and global reach, aligning with the Competitors Landscape of Organigram Holdings. As of March 2025, institutional ownership stood at 4.82%, indicating growing interest from institutional investors in Organigram Holdings Inc. shareholders.

Strategic Investment Impact

The significant investment from BAT has solidified its role as a major stakeholder. This partnership provides substantial capital for exploring new cannabis ventures globally. It underscores the increasing influence of strategic alliances in the evolving cannabis market.

Market Consolidation and Expansion

Acquisitions like Motif Labs and Collective Project are key to Organigram's strategy. These moves enhance its market position in Canada and open new revenue streams in the U.S. beverage sector. This reflects a broader trend of consolidation within the industry.

Leadership Transition and Future Growth

The upcoming CEO transition marks a new chapter for the company. The outgoing CEO oversaw substantial revenue growth and capacity expansion. The search for a successor will focus on leading Organigram's next phase of development.

Investor Profile Trends

Organigram's investor profile is evolving, with increasing institutional ownership. The company's strategic international expansion and diversification efforts are attracting a wider range of Organigram investors. This indicates growing confidence in its long-term strategy.

Organigram Holdings Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔